Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 5/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | UGCG | Q16739 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906595 | 0.81 | FAAH (0.41) | FAAH | |
| SCHEMBL9906594 | 0.72 | FAAH (0.45) | FAAH | |
| SCHEMBL9906598 | 0.70 | HSD17B10 (0.64) | GAA | |
| SCHEMBL2376389 | 0.70 | POLB (0.65) | FAAH | |
| SCHEMBL2376394 | 0.70 | POLB (0.65) | FAAH | |
| SCHEMBL13540967 | 0.69 | OPRD1 (0.60) | TACR1CYP3A4 | |
| SCHEMBL17104831 | 0.68 | MEN1 (0.61) | FAAHGAA | |
| SCHEMBL1360960 | 0.67 | ALDH1A1 (0.55) | FAAHCYP3A4 | |
| SCHEMBL1360958 | 0.67 | ALDH1A1 (0.55) | FAAHCYP3A4 | |
| SCHEMBL3117108 | 0.67 | PPARG (0.47) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652039-B2 | Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis | SEQUELLA, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | C5, THPO, TERT | FAAH 2618/4885CYP51A1 3817/4885PYGL 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.